REDWOOD CITY, Calif., Nov. 01. 2022 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Margaret (“Meg”) Fitzgerald as Chief Legal Officer and General Counsel, effective immediately. In this role Ms. Fitzgerald leads the company’s legal and compliance functions and provides strategic guidance to the board and executive management team. She will direct to dr. Stephen Dilly, president and CEO of Codexis, reports.
“Meg is a seasoned legal executive and leader with extensive experience on routine and complex legal matters,” said Dr. Dilly said. “Meg brings valuable legal and business expertise on product development, commercial launches, compliance and intellectual property. I am excited to welcome Meg to the team. Meg’s skills will be critical as we continue to grow our business.”
“I am delighted to be joining Codexis at this exciting time in the Company’s development and I look forward to building on the team’s many achievements,” said Ms. Fitzgerald said. “Codexis is a leader in enzyme engineering, and I am honored to work with this talented executive team as we continue to deliver meaningful innovations across our core target markets.”
Ms. Fitzgerald brings over twenty years of experience across the biotechnology industry. Most recently, she served as General Counsel, Corporate Secretary and Chief Compliance Officer at Allakos, Inc., where she provided strategic legal advice on securities, litigation, IP strategy, clinical development and commercialization. Before Allakos, Ms. Fitzgerald Associate General Counsel and Privacy Officer at Aimmune Therapeutics, Inc. Previously, she served as Vice President of Corporate Law at ZS Pharma, Inc., where she chaired negotiations that led to the $2.7 billion sale of ZS Pharma to AstraZeneca. Earlier in her career, Ms. Fitzgerald increasingly senior leadership roles at Genentech, Inc. holding, eventually serving as associate general counsel and director of transactional law. Ms. Fitzgerald also served as an associate attorney at Pillsbury Winthrop Shaw Pittman. She holds a JD from the University of California, Berkeley, as well as an MA and a BA in History from Stanford University.
Codexis is a leading enzyme engineering company that uses its proprietary CodeEvolver® platform to discover and develop new high-performance enzymes and biotherapeutics. Codexis enzymes have applications in the sustainable production of pharmaceuticals, food and industrial products; in the creation of the next generation of life science tools; and as gene therapy and oral enzyme therapies. The Company’s unique performance enzymes drive improvements such as: reduced energy consumption, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more effective therapeutic agents. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit www.codexis.com.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements that reflect management’s current beliefs and expectations made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 .You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are in some cases beyond Codexis’ control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2022 and in Codexis’ Quarterly Report on Form 10 – Q filed with the SEC on August 5, 2022, including under the heading “Risk Factors,” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intention or obligation to update these forward-looking statements, except as required by law.
Investor Relations Contact:
Brendan Strong/Carrie McKim